Recently Featured

Long-Range Gene Networks Uncover 641 New Schizophrenia-Associated Genes

June 30, 2026
Schizophrenia’s genetic landscape just expanded dramatically. A new study in Nature Genetics identifies 641 previously unrecognized genes associated with schizophrenia, thanks to a modeling framework that captures how distant genetic variants regulate gene expression through co-expression networks. The work reframes schizophrenia not as a collection of isolated genetic hits, but as a disorder shaped by…

Pfizer’s Sigvotatug Vedotin Fails to Meet Expectations in Lung Cancer Trial

June 30, 2026
Pfizer announced on Monday that its experimental lung cancer drug, sigvotatug vedotin, did not achieve the desired outcomes in a recent clinical trial, raising concerns about its viability as a replacement for the established chemotherapy docetaxel. The anticipation surrounding sigvotatug vedotin was significant, with Pfizer’s CEO, Albert Bourla, previously suggesting it could be a pivotal…

AI Discovers Potential Antimicrobial “Prionin” Peptides

June 30, 2026
Researchers at the University of Pennsylvania have identified a novel class of antimicrobial peptides, termed “prionins,” derived from prion and prion-like proteins. Utilizing a deep learning platform named APEX 1.1, the team screened millions of protein fragments, uncovering over a thousand candidates, with 59 shown to inhibit various bacterial pathogens, including drug-resistant strains. This discovery…

FDA Actions to Accelerate and Modernize Early and Late-Stage Clinical Development

June 30, 2026
The FDA has announced a series of initiatives aimed at accelerating and modernizing clinical research, addressing both early and late-stage drug development processes. These actions encompass the entire continuum of drug development, from the Investigational New Drug (IND) phase through to late-stage pivotal trials, reflecting the agency’s commitment to enhancing efficiency and responsiveness in clinical…

Ongoing Cases